BRPI0502016B8 - ureid compounds, pharmaceutical compositions containing them and their use in the treatment of inflammatory diseases - Google Patents

ureid compounds, pharmaceutical compositions containing them and their use in the treatment of inflammatory diseases

Info

Publication number
BRPI0502016B8
BRPI0502016B8 BRPI0502016A BRPI0502016A BRPI0502016B8 BR PI0502016 B8 BRPI0502016 B8 BR PI0502016B8 BR PI0502016 A BRPI0502016 A BR PI0502016A BR PI0502016 A BRPI0502016 A BR PI0502016A BR PI0502016 B8 BRPI0502016 B8 BR PI0502016B8
Authority
BR
Brazil
Prior art keywords
inflammatory
derivatives
treatment
pharmaceutical compositions
compositions containing
Prior art date
Application number
BRPI0502016A
Other languages
Portuguese (pt)
Inventor
Légora Machado Alexandre
Alberto Manssour Fraga Carlos
Jesus De Lacerda Barreiro Eliezer
Medeiros de Carvalho Fátima
Marcelo Sperândio Da Silva Gilberto
Eduardo Menezes Quintas Luis
Moreira Lima Lídia
Lúcia Goncalves Koatz Vera
Original Assignee
Univ Federal Do Rio De Janeiro Ufrj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Federal Do Rio De Janeiro Ufrj filed Critical Univ Federal Do Rio De Janeiro Ufrj
Priority to BRPI0502016A priority Critical patent/BRPI0502016B8/en
Priority to PCT/BR2006/000107 priority patent/WO2006128268A1/en
Publication of BRPI0502016A publication Critical patent/BRPI0502016A/en
Publication of BRPI0502016B1 publication Critical patent/BRPI0502016B1/en
Publication of BRPI0502016B8 publication Critical patent/BRPI0502016B8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

compostos ureídicos, composições farmacêuticas contendo os mesmos e seu uso no tratamento de doenças inflamatórias. a presente invenção relata derivados 6-n-alquil e/ou 6-n-aril ureias [1,3]dioxolo[5,4-g]quinolina-7-carboxilato de etila funcionalizados (3a-z, 4a-z); e congêneres (5a-z), de fórmula geral (i, ii, iii e iv), úteis no tratamento e/ou prevenção de doenças de origem inflamatória, tais como quadros inflamatórios, propriamente ditos, agudos ou crônicos, diferentes tipos de artrite, asma, doença de crohn e diabetes mellitus do tipo i, entre outras. esses derivados possuem a capacidade de modular o processo inflamatório atuando em nível da proteína cinase ativada por mitógeno p-38 (mapk-p38). ademais, os derivados da presente invenção apresentam expressivas propriedades antiinflamatórias aferidas em modelos in vivo. a presente invenção também revela processos para a produção de tais derivados e composições farmacêuticas contendo os mesmos.ureid compounds, pharmaceutical compositions containing them and their use in the treatment of inflammatory diseases. the present invention reports functionalized ethyl 6-n-alkyl and/or 6-n-aryl ureas [1,3]dioxolo[5.4-g]quinoline-7-carboxylate derivatives (3a-z, 4a-z); and congeners (5a-z), of general formula (i, ii, iii and iv), useful in the treatment and/or prevention of diseases of inflammatory origin, such as inflammatory conditions, per se, acute or chronic, different types of arthritis , asthma, Crohn's disease and type I diabetes mellitus, among others. these derivatives have the ability to modulate the inflammatory process acting at the level of the p-38 mitogen-activated protein kinase (mapk-p38). furthermore, the derivatives of the present invention have expressive anti-inflammatory properties measured in in vivo models. the present invention also discloses processes for the production of such derivatives and pharmaceutical compositions containing them.

BRPI0502016A 2005-06-03 2005-06-03 ureid compounds, pharmaceutical compositions containing them and their use in the treatment of inflammatory diseases BRPI0502016B8 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRPI0502016A BRPI0502016B8 (en) 2005-06-03 2005-06-03 ureid compounds, pharmaceutical compositions containing them and their use in the treatment of inflammatory diseases
PCT/BR2006/000107 WO2006128268A1 (en) 2005-06-03 2006-06-01 Ureidic compounds, pharmaceutical compositions containing the same and their use on the treatment of inflammatory diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0502016A BRPI0502016B8 (en) 2005-06-03 2005-06-03 ureid compounds, pharmaceutical compositions containing them and their use in the treatment of inflammatory diseases

Publications (3)

Publication Number Publication Date
BRPI0502016A BRPI0502016A (en) 2007-01-23
BRPI0502016B1 BRPI0502016B1 (en) 2019-06-04
BRPI0502016B8 true BRPI0502016B8 (en) 2021-05-25

Family

ID=37481168

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0502016A BRPI0502016B8 (en) 2005-06-03 2005-06-03 ureid compounds, pharmaceutical compositions containing them and their use in the treatment of inflammatory diseases

Country Status (2)

Country Link
BR (1) BRPI0502016B8 (en)
WO (1) WO2006128268A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
BRPI1004176A2 (en) * 2010-10-25 2015-08-11 Univ Rio De Janeiro Functionalized aryl and / or heteroaryl urea compounds; synthesis process of these compounds; pharmaceutical composition containing such compounds and uses
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
RU2686692C1 (en) * 2018-06-29 2019-04-30 Федеральное Государственное Бюджетное Учреждение Науки Институт Биохимической Физики Им. Н.М. Эмануэля Российской Академии Наук (Ибхф Ран) Use of n-(6,8,8-trimethyl-8,9-dihydrofuro[3,2-h]quinolin-5-yl)acetamide as an agent for phototherapy of psoriasis and psoriatic arthritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132496A (en) * 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
EP1545514A1 (en) * 2002-08-14 2005-06-29 Boehringer Ingelheim Pharmaceuticals Inc. Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
CA2516931C (en) * 2003-02-28 2014-09-09 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders

Also Published As

Publication number Publication date
WO2006128268A8 (en) 2007-04-26
BRPI0502016A (en) 2007-01-23
BRPI0502016B1 (en) 2019-06-04
WO2006128268A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
BRPI0507309A (en) 7-phenylamino-4quinolon-3-carboxylic acid derivatives, processes for production and their use as a medicine
BR0309167A (en) Compound, process for producing a compound, pharmaceutical composition, use of the compound, method for treating a subject affected by a pathological condition or disease and combination product
WO2008003766A3 (en) 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
BRPI0910439B8 (en) thienopyridone derivatives as amp-activated protein kinase (ampk) activators, their preparation process, and medicines
UY28990A1 (en) NEW DERIVATIVES OF BENZENE 1, 3-CARBON AMINO AS B-RAF INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION AND USE PROCESSES.
BRPI0407253A (en) Heterocyclyl-3-sulfonylindazoles as ligands 5-hydroxytryptamine-6 process for their preparation, their uses in the preparation of a pharmaceutical composition and a pharmaceutical composition comprising said compounds
BRPI0515485A (en) heteroaryl compounds as betamimetics for the treatment of respiratory diseases
WO2007071963A3 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
BRPI0910832B8 (en) thienopyridone derivatives as amp-activated protein kinase (ampk) activators, their uses, their preparation process and their intermediates, and drugs.
BRPI0511874A (en) pyrrolopyridine derivatives
MX2009003958A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof.
WO2009098715A3 (en) Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
MX2007008924A (en) Chemical compounds.
CU20120013A7 (en) OXACINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
BR0208887A (en) Dihydro-benzo derivatives [b] [1,4] diazepin-2-one as mglur2 i antagonists
WO2007113558A3 (en) Quinazolinone derivatives having b-raf inhibitory activity
BRPI0608178A2 (en) aminopyrazole derivatives, their manufacture, pharmaceutical composition and use as pharmaceutical agents
ECSP088541A (en) [(1H-INDOL-5-IL) -HETEROARILOXI] - (1-AZA-BICICLO [3.3.1] NONANS AS N-ACHR COLLINERIC LINKS FOR THE TREATMENT OF PSYCHOTIC AND NEURODEGENERATIVE DISORDERS
BRPI0508177A (en) compound, process for the production of compound, pharmaceutical composition, use of compound method for treating a disease and combination product
WO2008080844A9 (en) Azaspiro derivatives
UY29092A1 (en) DERIVATIVES OF 4-OXO-3,4-DIHIDROQUINAZOLIN-6-CARBOXAMIDA, B-RAF INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
BRPI0815547B8 (en) pharmaceutical composition comprising cyclic depsipeptides, and their uses
MX2009005507A (en) Spiro-piperidine derivatives.
BRPI0507313A (en) heterocyclically substituted 7-amino-4-quinolon-3-carboxylic acid derivatives, process for their preparation and use as a medicine
ATE435864T1 (en) SUBSTITUTED 5,6,7,8-TETRAHYDRO-IMIDAZOÄ1,2-AUPYRIDINE-2-YLAMIN COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICINAL PRODUCTS

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled

Free format text: REFERENTE A RPI 2021 DE 29/09/2009.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/06/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF